

Notes from the Field

Use of Enhanced Surveillance to Detect Severe Group A *Streptococcus* Infections Among Persons Experiencing Homelessness — Missoula County, Montana, July 2024–September 2025

Beth Hopkins, MPH¹; Ashley A. Meehan, PhD²;
Stephen G. Mugal, PhD^{3,4}; B-Rad Applegate, PhD⁵; Sarah Black, MPH⁵;
Joe B. B. Silva, PhD^{3,4}; Jeffery Mutuc, MD^{3,4}; Kirsten Edwards⁵;
Josy Jahnke⁵; Pam Whitney, MPH⁵; Michelle Mozer¹; Sopio Chochua, MD,
PhD⁴; Victoria Doll, MPH¹; Erika Baldry, MPH¹; Jessica Lopeman, MPH¹;
Cindy Farr⁵; Christopher J. Gregory, MD⁴; Laura Williamson, MPH¹;
Cedar L. Mitchell, PhD^{1,2}

Group A *Streptococcus pyogenes* (GAS) infections cause diverse clinical manifestations, including noninvasive disease such as skin or wound infections and invasive disease, which can result in severe illness and death (1). Skin breakdown from wounds, including blunt or penetrating trauma, burns, environmental exposure, and pressure ulcers, is common among persons experiencing homelessness and can contribute to invasive infections (2). In this population, the incidence of invasive GAS (iGAS)* disease is approximately 100 times that of the general population (3). Because of the potential for iGAS to cause severe disease, iGAS became a reportable condition in Montana on July 27, 2024 (4).

During November 2024–August 2025, routine disease surveillance by the Montana Department of Public Health and Human Services (DPHHS) detected 20 cases of invasive and noninvasive GAS infection epidemiologically linked to two homeless shelters in Missoula and raised concern about potential increased infections among persons experiencing homelessness. DPHHS requested epidemiologic assistance (Epi-Aid) from CDC to conduct enhanced surveillance and characterize GAS infections among persons experiencing homelessness in Missoula. Written consent was obtained from local health care facilities to review records. This activity was reviewed by CDC, deemed not

research, and conducted consistent with applicable federal law and CDC policy.[†]

Investigation and Outcomes

Enhanced GAS Surveillance

In September 2025, enhanced disease surveillance activities were initiated to improve detection of GAS infections and systematically capture additional epidemiologic data, including housing status. Enhanced surveillance activities included 1) obtaining laboratory reports and medical records directly from local health care facilities, 2) abstracting clinical and epidemiologic information, and 3) sequencing available GAS isolates using whole-genome sequencing methods at the Utah Public Health Laboratory and CDC. The surveillance period was extended retrospectively to capture all GAS cases during July 27, 2024–September 20, 2025. Case definitions were developed for GAS infection (iGAS, severe noninvasive GAS, and nonsevere noninvasive GAS)[§] and for homelessness (confirmed or probable).[¶]

[†] 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

[§] GAS severity was classified as 1) invasive GAS, defined as a GAS-positive culture from a normally sterile body site, streptococcal toxic shock syndrome, or necrotizing soft tissue infection; 2) severe noninvasive GAS, defined as a GAS-positive culture (excluding throat culture) isolated from a nonsterile site (e.g., wound) in a person who was hospitalized or was recommended to be hospitalized but who left against medical advice; or 3) nonsevere noninvasive GAS, defined as a GAS-positive culture (excluding throat culture) isolated from a nonsterile site in a person who was not hospitalized or was not recommended to be hospitalized.

[¶] 1) Confirmed homelessness: documentation of service use in the Homeless Management Information System, or documentation of homelessness in a patient's medical record (e.g., history of illness, nursing notes, social history notes, or discharge notes); 2) Probable homelessness: an address associated with a homeless service provider or homeless shelter without documentation of homelessness in the medical record.

INSIDE

630 QuickStats

Continuing Education examination available at
https://www.cdc.gov/mmwr/mmwr_continuingEducation.html

* iGAS was defined as a GAS-positive culture isolated from a normally sterile body site, streptococcal toxic shock syndrome, or necrotizing soft tissue infection.



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

Characteristics of GAS Infections

Sixty-nine GAS cases were identified (Figure), 39 (57%) of which (including three reinfections)** occurred among 36 persons with confirmed or probable homelessness. Among the 39 cases of GAS infection among persons experiencing homelessness, eight were identified through extension of the surveillance period, and 10 were identified through other enhanced surveillance methods, including six from directly obtained laboratory reports and four from housing information in medical records. Among all 39 cases of GAS infection in persons experiencing homelessness, 34 (87%) required hospitalization, including the 15 (38%) iGAS infections; one iGAS infection resulted in death. Among the three reinfections among persons experiencing homelessness, all three patients had invasive disease for both their initial infection and their reinfection; two patients were hospitalized for both of their infections, whereas one patient was hospitalized for their initial infection only.

Thirty (43%) of the 69 cases of GAS infection were identified among persons not experiencing homelessness; no reinfections occurred among this group. Eighteen (60%) infections resulted in a hospitalization, including nine (50%) iGAS infections. During the surveillance period, the estimated incidence of GAS infections among persons experiencing homelessness (2,285.2 per 100,000 person-years) was 106.1 times

(95% CI = 65.9–170.7) that in Missoula County's general population (21.5 per 100,000 person-years).^{††}

At the time of diagnosis, wounds or skin breakdown were present in 34 (87%) of the 39 cases of GAS infection among persons experiencing homelessness. History of substance use was common (27; 69%), and injection drug use, a known iGAS risk factor (3), was documented in 10 (26%) patient encounters. Data from 23 isolates revealed six M protein gene (*emm*) types,^{§§} suggesting genetic diversity among infections and multiple transmission chains.

Preliminary Conclusions and Actions

Persons experiencing homelessness experience a disproportionately high incidence of GAS infection; therefore, early detection in this population to prevent severe disease remains a high priority (3). The identification of 18 (46%) additional

^{††} GAS incidence among persons experiencing homelessness was estimated at 2,285.2 per 100,000 person-years for 39 cases among a population denominator of 1,484 persons derived from the Missoula Community Houselessness Strategy 2024 annual estimate. GAS incidence among persons not experiencing homelessness was estimated at 21.5 per 100,000 person-years for 30 cases among a population denominator of 121,062 persons in Missoula County, obtained by subtracting the estimate among persons experiencing homelessness (1,484) from the total Missoula County U.S. Census Bureau 2024 population projection (122,546). The surveillance period was 1.15 years.

^{§§} [Group A streptococci are classified into >275 *emm* types, based on sequence analysis of part of the cell surface M \(virulence\) protein.](#) Among the 23 isolates, the dominant *emm* types were *emm* 49 (detected in nine isolates) and *emm* subtype 58.2 (detected in 10 isolates). In the remaining four isolates, one *emm* type (53, 76, 85, or 92) was detected in each isolate.

** Reinfections were defined as reisolation of GAS in a person with a documented previous GAS infection ≥ 30 days after the previous isolation.

The *MMWR* series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. *MMWR Morb Mortal Wkly Rep* 2026;75:[inclusive page numbers].

Centers for Disease Control and Prevention

Erica Schwartz, MD, MPH, JD, *Director*
Jennifer A. Shuford, MD, MPH, *Deputy Director and Chief Medical Officer*
Althea Grant-Lenzy, PhD, MSS, *Director, Office of Science*

MMWR Editorial and Production Staff (Weekly)


Leonard Jack, Jr, PhD, MSc, *Acting Editor in Chief*
Jacqueline Gindler, MD, *Editor*
Mary Dott, MD, MPH, *Online Editor*
Terisa F. Rutledge, *Managing Editor*
Catherine B. Lansdowne, MS, *Lead Technical Writer-Editor*
Stacy Simon, MA, Morgan Thompson, Suzanne Webb, PhD, MA, *Technical Writer-Editors*
Terraye M. Starr, *Acting Lead Health Communication Specialist*
Alexander J. Gottardy, Maureen A. Leahy, *Visual Information Specialists*
Quang M. Doan, MBA, Phyllis H. King, Moua Yang, *Information Technology Specialists*

Lowery Johnson, *Health Communication Specialist*
Will Yang, MA, *Visual Information Specialist*

MMWR Editorial Board

Timothy F. Jones, MD, *Chairman*
Matthew L. Boulton, MD, MPH
Carolyn Brooks, ScD, MA
Virginia A. Caine, MD
Jonathan E. Fielding, MD, MPH, MBA
David W. Fleming, MD
William E. Halperin, MD, DrPH, MPH
Jewel Mullen, MD, MPH, MPA
Jeff Niederdeppe, PhD
Patricia Quinlisk, MD, MPH
Patrick L. Remington, MD, MPH
Carlos Roig, MS, MA
William Schaffner, MD
Morgan Bobb Swanson, MD, PhD

FIGURE. Number and percentage of group A *Streptococcus* infections* among persons experiencing homelessness^{†,§} and not experiencing homelessness, by hospitalization status of patients and severity of infection[¶] — Missoula County, Montana, July 27, 2024–September 20, 2025



Abbreviation: GAS = group A *Streptococcus*.

* All numbers refer to cases of GAS infection. Invasive GAS was defined as a GAS-positive culture from a normally sterile body site, streptococcal toxic shock syndrome, or necrotizing soft tissue infection. Severe GAS was defined as a GAS-positive culture (excluding throat culture) isolated from a nonsterile site (e.g., wound) in a person who was hospitalized or was recommended to be hospitalized but who left against medical advice. Nonsevere GAS was defined as a GAS-positive culture (excluding throat culture) isolated from a nonsterile site in a person who was not hospitalized or was not recommended to be hospitalized.

[†] Housing status was classified as homeless if a person had documentation of service use in the Homeless Management Information System, documentation of homelessness in their medical record (e.g., history of illness, nursing notes, social history notes, or discharge notes), or a had an address associated with a homeless service provider or homeless shelter.

[§] The 39 infections occurred among 36 persons and included three cases of reinfection. Among the three reinfections among persons experiencing homelessness, all three patients had invasive disease for both the initial infection and the reinfection. Two patients were hospitalized for both of their infections, whereas one patient was hospitalized for the initial infection but not the reinfection.

[¶] One of the 15 persons experiencing homelessness who was hospitalized with invasive GAS died.

Summary

What is already known about this topic?

The incidence of invasive group A *Streptococcus* (GAS) infection among persons experiencing homelessness is approximately 100 times that among persons in the general population.

What is added by this report?

During July 27, 2024–September 20, 2025, a total of 69 GAS cases were identified in Missoula, Montana, using routine and enhanced disease surveillance; 39 (57%) cases (including three reinfections) occurred among 36 persons experiencing homelessness; 18 (46%) of these cases were identified through enhanced surveillance activities. Enhancing surveillance data to capture housing information improved homelessness classification among GAS patients and enhanced detection of GAS cases.

What are the implications for public health practice?

The disproportionately high incidence of GAS infection among persons experiencing homelessness that was missed by routine surveillance activities highlights areas for improving early case detection to prevent severe disease, case classification, and opportunities to prevent further spread.

GAS cases among persons experiencing homelessness, through enhanced surveillance or retrospective extension of the surveillance period, highlighted the usefulness of enhanced surveillance for an emerging public health concern among a population at high risk for infection. Estimating the incidence of GAS among persons experiencing homelessness remains a challenge because of differential barriers to accessing health care and case ascertainment by housing status, dynamic population denominators and limited enumeration data, and incomplete classification of housing status; thus, these findings likely underestimate the true incidence of GAS infection among persons experiencing homelessness. DPHHS now routinely collects housing status data during iGAS investigations to improve disease detection in this population (5) and facilitate prompt public health action to prevent further spread. The department is also exploring thresholds for increasing and decreasing enhanced surveillance activities to respond to GAS cases and other emerging public health events.

Corresponding author: Beth Hopkins, beth.hopkins@mt.gov.

¹Montana Department of Public Health and Human Services; ²Career Epidemiology Field Officer Program, CDC; ³Epidemic Intelligence Service, CDC; ⁴Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC; ⁵Missoula Public Health, Missoula, Montana.


All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. CDC. Group A strep infection: about group A strep infection. Atlanta, GA: US Department of Health and Human Services, CDC; 2025. <https://www.cdc.gov/group-a-strep/about/index.html>
2. Gall B, Kirkland-Kyhn H, Sengul T. Wounds in the unhoused population. *Nurs Clin North Am* 2025;60:119–27. PMID:39884784 <https://doi.org/10.1016/j.cnur.2024.07.007>
3. Gregory CJ, Okaro JO, Reingold A, et al. Invasive group A streptococcal infections in 10 US states. *JAMA* 2025;333:1498–507. PMID:40193120 <https://doi.org/10.1001/jama.2025.0910>
4. Administrative Rules of Montana. 37.114.203 Reportable diseases and other conditions of public health importance. Helena, MT: Administrative Rules of Montana; 2026. <https://rules.mt.gov/browse/collections/aec52c46-128e-4279-9068-8af5d5432d74/policies/a10d456a-4ef9-43d1-a9a8-93d7b010e4ed>
5. Jones PS, Yeh KW, Brosnan HK, et al. Evaluation of the homeless management information system for COVID-19 surveillance among people experiencing homelessness. *J Infect Dis* 2022;226(Suppl 3):S327–34. PMID:36208169 <https://doi.org/10.1093/infdis/jiac335>

QuickStats

FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

Percentage* of Children and Adolescents Aged 5–17 Years Who Had Ever Received a Diagnosis of Attention-Deficit/Hyperactivity Disorder, by Sex and Year — United States, 2019–2025**Abbreviation:** ADHD = attention-deficit/hyperactivity disorder.

* Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population.

From 2019 to 2025, the percentage of children and adolescents aged 5–17 years who had ever received a diagnosis of ADHD increased from 9.9% to 13.8%. The percentage of boys and girls with ADHD diagnoses increased throughout this period; a higher percentage of boys than girls had ever received a diagnosis of ADHD.

Supplementary Table: [Percentage of Children and Adolescents Aged 5–17 Years Who Had Ever Received a Diagnosis of Attention-Deficit/Hyperactivity Disorder, by Sex and Year — United States, 2019–2025](#)

Source: National Center for Health Statistics, National Health Interview Survey, 2019–2025. [About NHIS](#) | [National Health Interview Survey](#) | [CDC](#)

Reported by: Nazik Elgaddal, MS, nelgaddal@cdc.gov.

For more information on this topic, CDC recommends the following link: [Attention-Deficit / Hyperactivity Disorder \(ADHD\) | CDC](#).

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the U.S. Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR* at <https://www.cdc.gov/mmwr/index.html>.

Readers who have difficulty accessing this PDF file may access the HTML file at <https://www.cdc.gov/mmwr/index2026.html>. Address all inquiries about the *MMWR* Series to Editor-in-Chief, *MMWR* Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

MMWR and *Morbidity and Mortality Weekly Report* are service marks of the U.S. Department of Health and Human Services.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

ISSN: 0149-2195 (Print)